References
[1] CASADEVALL A, PIROFSKI L A.A new synthesis for antibody-mediated immunity[J].Nature immunology, 2012, 13(1):21-28.
[2] KAPLON H, REICHERT J M.Antibodies to watch in 2019[J].MAbs-Austin, 2019,11:219-238.
[3] LU R M, HWANG Y C, LIU I J, et al.Development of therapeutic antibodies for the treatment of diseases[J].Journal of biomedical science, 2020, 27(1):1.
[4] KÖHLER G, MILSTEIN C.Continuous cultures of fused cells secreting antibody of predefined specificity[J].Nature, 1975, 256(5517):495-497.
[5] STERN M, HERRMANN R.Overview of monoclonal antibodies in cancer therapy: present and promise[J].Critical review in oncology/hematology, 2005, 54(1):11-29.
[6] OSBORN M J, MA B, AVIS S.High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH region[J].The journal of immunology, 2013, 190(4):1481-1490.
[7] KWAKKENBOS M J, VAN HELDEN PM, BEAUMONT T, et al.Stable long-term cultures of self-renewing B cells and their applications[J].Immunological reviews, 2016,270(1):65-77.
[8] LONBERG N.Human antibodies from transgenic animals[J].Nature biotechnology, 2005,23(9):1117-1125.
[9] OUISSE L H, GAUTREAU-ROLLAND L, DEVILDER M C.Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies[J].BMC biotechnology, 2017, 17:1.
[10] CHAISRI U, CHAICUMPA W.Evolution of therapeutic antibodies, influenza virus biology,influenza, and influenza immunotherapy[J].BioMed research international, 2018,2018:9747549.
[11] DAUGHERTY P S, OLSEN M J, IVERSON B L, et al.Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface[J].Protein engineering, design and selection, 1999, 12(7):613-621.
[12] BEERLI R R, BAUER M, BUSER R B.Isolation of human monoclonal antibodies by mammalian cell display[C]//Proceedings of the National Acadamy of Sciences of the United States of America, 2008, 105(38):14336-14341.
[13] HOOGENBOOM H R.Overview of antibody phage-display technology and its application[J].Antibody phage display: methods and protocol, 2002, 1-37.
[14] JOBLING S A, JARMAN C, TEH M M, et al.Immunomodulation of enzyme function in plants by single-domain antibody fragments[J].Nature biotechnology, 2003, 21(1):77-80.
[15] THANONGSAKSRIKUL J, SRIMANOTE P, MANEEWATCH S.A VHH that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A[J].The journal of biological chemistry, 2010, 285(13):9657-9666.
[16] NELSON A L, REICHERT J M.Development trends for therapeutic antibody fragments[J].Nature biotechnology, 2009, 27(4):331-337.
[17] DE MEYER T, MUYLDERMANS S, DEPICKER A.Nanobody-based products as research and diagnostic tools[J].Trends in biotechnology, 2014, 32(5):263-270.
[18] POOGA M, KUT C, KIHLMARK M.Cellular translocation of proteins by transportan.The FASEB journal, 2001, 15(8):1451-1453.
[19] HEITZ F, MORRIS M C, DIVITA G .Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics.British journal of pharmacology, 2009, 157(2):195-206.
[20] NOGUCHI H, MATSUMOTO S.Protein transduction technology: a novel therapeutic perspective.Acta medica okayama, 2006, 60(1):1-11.
[21] MARABELLE A, GRAY J.Tumor-targeted and immune-targeted monoclonal antibodies:going from passive to active immunotherapy[J].Pediatr blood cancer, 2015, 62(8):1317-1325.
[22] MELLMAN I, COUKOS G, DRANOFF G .Cancer immunotherapy comes of age[J].Nature,2011, 480:480-489.
[23] WOLCHOK J D, HOOS A, O’DAY S, et al.Guidelines for the evaluation of immune therapy activity in solid tumors: immune related response criteria[J].Clinical cancer research,2009, 15:7412-7420.
[24] HALES R K, BANCHEREAU J, RIBAS A, et al.Assessing oncologic benefit in clinical trials of immunotherapy agents[J].Annual oncology, 2010, 21:1944-1951.
[25] SCHADENDORF D.Pooledanalysis of long-term survival data from phaseII and phaseIII trial sofipilimumab in metastatic or locally advanced, unresectable melanoma[J].Nature review clinical oncology, 2013, 2013:10.
[26] TUMEH P C, HARVIEW C L, YEARLEY J H, et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance[J].Nature, 2014, 515:568-571.
[27] HERBST R S, SORIA J-C, KOWANETZ M, et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL 3280A in cancer patients[J].Nature, 2014, 515:563-567.
[28] WOLCHOK J D, KLUGER H, CALLAHAN M K, et al.Nivolumab plus Ipilimumab in advanced melanoma[J].New England journal of medicine, 2013, 369(2):122-133.
[29] HANAHAN D, WEINBERG R A.Hallmarks of cancer: the next generation[J].Cell, 2011,144:646-74.
[30] KALLURI R, ZEISBERG M.Fibroblasts in cancer[J].Nature review cancer, 2006,6:392-401.
[31] VON HOFF D D, ERVIN T, ARENA F P, et al.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J].New England journal of medicine, 2013, 369:1691-703.
[32] BELLI C, TRAPANI D, VIALE G, et al.Targeting the microenvironment in solid tumors[J].Cancer treatment review, 2018, 65:22-32.(https://www.daowen.com)
[33] CARMELIET P.Angiogenesis in health and disease[J].Nature medicine, 2003, 9:653-660.
[34] SEMENZA G L.Targeting HIF1 for cancer therapy[J].Nature review cancer, 2003,3:721-732.
[35] HARLAAR N J, KOLLER M, DE JONGH S J, et al.Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study[J].Lancet gastroenterol, 2016, 1:283-290.
[36] ROMA-RODRIGUES C, MENDES R, BAPTISTA P V, et al.Targeting tumor microenvironment for cancer therapy[J].International journal of molecular sciences, 2019,20:840.
[37] YANG L, PANG Y, MOSES H L.TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression[J].Trends immunology, 2010, 31:220-227.
[38] DIAZ-VALDES N, BASAGOITI M, DOTOR J, et al.Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression[J].Cancer research, 2011, 71:812-821.
[39] GUPTA S C, KIM J H, KANNAPPAN R, et al.Role of nuclear factor kappaB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents[J].Expert biology medicine, 2011, 236:658-671.
[40] UGEL S, DE SANCTIS F, MANDRUZZATO S, et al.Tumor-induced myeloid deviation:when myeloid-derived suppressor cells meet tumor-associated macrophages[J].Journal of clinical investigation, 2015, 125: 3365-3376.
[41] DIJKGRAAF E M, SANTEGOETS S J, REYNERS A K, et al.A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer[J].Annual oncology,2015, 26:2141-2149.
[42] KOPP H G, AVECILLA S T, HOOPER A T, et al.The bone marrow vascular niche: home of HSC differentiation and mobilization[J].Physiology, 2005, 20:349-356.
[43] CHITU V, STANLEY E R.Colony-stimulating factor-1 in immunity and inflammation[J].Current opinion immunology, 2006, 18:39-48.
[44] FINKERNAGEL F, REINARTZ S, LIEBER S, et al.The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization[J].Oncotarget, 2016, 7:5339-5752.
[45] HYNES R O.The extracellular matrix: not just pretty fibrils[J].Science, 2009,326:1216-1219.
[46] BESSE B, TSAO L C, CHAO D T, et al.Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer[J].Annual oncology, 2013, 24:90-96.
[47] SHARONOV G V, SEREBROVSKAYA E O, YUZHAKOVA D V, et al.B cells, plasma cells and antibody repertoires in the tumour microenvironment[J].Nature review immunology, 2020, 20(5):294-307.
[48] FREMD C.Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients[J].Oncoimmunology, 2016, 5: e1057387.
[49] DEFALCO J.Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens[J].Clinical immunology, 2018,187:37-45.
[50] MONTFORT A.A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases[J].Clinical cancer research, 2017, 23:250-262.
[51] BAKER K.Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer[J].Immunity, 2013, 39:1095-1107.
[52] COLBECK E J, AGER A, GALLIMORE A, et al.Tertiary lymphoid structures in cancer:drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?[J].Frontiers in immunology, 2017, 8:1830.
[53] SHARONOV G V, SEREBROVSKAYA E O, YUZHAKOVA D V, et al.B cells, plasma cells and antibody repertoires in the tumour microenvironment[J].Nature review immunology, 2020, 20(5):294-307.
[54] BAUCHE D, MARIE J C.Transforming growth factor β: a master regulator of the gut microbiota and immune cell interactions[J].Clinical translation immunology, 2017, 6: e136.
[55] DISIS M L, WATT W C, CECIL D L.Th1 epitope selection for clinically effective cancer vaccines[J].Oncoimmunology, 2014, 3: e954971.
[56] HARADA K, NAKANUMA Y.Cholangiocarcinoma with respect to IgG4 reaction[J].Hepatology international, 2014, 80:3876.
[57] ZHAO J, NUSSINOV R, MA B.Antigen binding allosterically promotes Fc receptor recognition[J].MAbs, 2019, 11:58-74.
[58] BOWEN A, CASADEVALL A.Revisiting the immunoglobulin intramolecular signaling hypothesis[J].Trends immunology, 2016, 37:721-723.
[59] VOLLMERS C, SIT R V, WEINSTEIN J A, et al.Genetic measurement of memory B-cell recall using antibody repertoire sequencing[C]//Proceedings of the National Academy of Sciences of the United States of America, 2013, 110:13463-13468.
[60] CANZAR S, NEU K E, TANG Q, et al.BASIC: BCR assembly from single cells[J].Bioinformatics, 2017, 33:425-427.
[61] MENG Q, VALENTINI D, RAO M, et al.KRAS RENAISSANCE(S) in tumor infiltrating B cells in pancreatic cancer[J].Frontiers in oncology, 2018, 8:384.
[62] SEAH Y F S, HU H, MERTEN C A.Microfluidic single-cell technology in immunology and antibody screening[J].Molecular aspect medicine, 2018, 59:47-61.
[63] BUSSE C E, CZOGIEL I, BRAUN P, et al.Single-cell based high-throughput sequencing of full-length immunoglobulin heavy and light chain genes[J].European journal of immunology, 2014, 44: 597-603.